Neuroleptic malignant syndrome and clozapine monotherapy - Comment

被引：0
|
作者：
Lee, JWY
机构：
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 1997年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [21] CLOZAPINE RECHALLENGE AFTER AN EPISODE OF NEUROLEPTIC MALIGNANT SYNDROME
    WELLER, M
    KORNHUBER, J
    BRITISH JOURNAL OF PSYCHIATRY, 1992, 161 : 855 - 856
  • [22] Neuroleptic malignant syndrome following initiation of clozapine therapy
    Dalkilic, A
    Grosch, WN
    AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (06): : 881 - 882
  • [23] A CASE OF CLOZAPINE-INDUCED NEUROLEPTIC MALIGNANT SYNDROME
    MILLER, DD
    SHARAFUDDIN, MJA
    KATHOL, RG
    JOURNAL OF CLINICAL PSYCHIATRY, 1991, 52 (03) : 99 - 101
  • [24] Neuroleptic malignant syndrome can occur with clozapine or risperidone
    Reactions Weekly, 1998, 715 (1) : 2 - 2
  • [25] Clozapine-Induced Neuroleptic Malignant Syndrome in an Adolescent
    Matheson, Katherine M.
    Gray, Gerald
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2012, 22 (04) : 322 - 324
  • [26] Suspected neuroleptic malignant syndrome in a patient receiving clozapine
    Ganelin, L
    Lichtenberg, PS
    Marcus, EL
    Munter, G
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (03) : 248 - 250
  • [27] NEUROLEPTIC MALIGNANT SYNDROME AFTER CLOZAPINE PLUS CARBAMAZEPINE
    MULLER, T
    BECKER, T
    FRITZE, J
    LANCET, 1988, 2 (8626-7): : 1500 - 1500
  • [28] Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy
    Wang, HC
    Hsieh, Y
    MOVEMENT DISORDERS, 2001, 16 (04) : 765 - 767
  • [29] Clozapine/haloperidolAtypical neuroleptic malignant syndrome and delirium: case report
    Reactions Weekly, 2020, 1835 (1) : 112 - 112
  • [30] Clozapine Rechallenge Following Neuroleptic Malignant Syndrome A Systematic Review
    Lally, John
    McCaffrey, Cathal
    O'Murchu, Conall
    Krivoy, Amir
    Guerandel, Allys
    MacCabe, James H.
    Gaughran, Fiona
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (04) : 372 - 379
12345